BDTX director granted 6,105 shares as compensation

Raman Prakash reported acquisition or exercise transactions in this Form 4 filing.

Accepted by SEC EDGAR 03/20/2026 - 05:19 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Raman Prakash reported acquisition or exercise transactions in this Form 4 filing.

Black Diamond Therapeutics director Raman Prakash received 6,105 shares of Common Stock as compensation. The shares were issued under the company’s non-employee director compensation policy, where he elected stock instead of cash for annual board service. The grant was valued at $2.15 per share, bringing his direct holdings to 37,132 shares.

Insider Trade Summary

Grant/Award: 6,105 shares

Grant/Award 1 txn

Insider Raman Prakash

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	6,105	$2.15	$13K

Holdings After Transaction: Common Stock — 37,132 shares (Direct)

Holdings Before and After: Common Stock, 31,027 to 37,132 shares (Direct)

Footnotes (2)

1. F1. These shares were issued in accordance with the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer.
2. F2. The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on March 19, 2026.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Black Diamond Therapeutics (BDTX) director Raman Prakash report?

Director Raman Prakash reported receiving 6,105 shares of Black Diamond Therapeutics common stock. The shares were granted as part of his annual non-employee director compensation, which he elected to take in stock rather than cash under the company’s director compensation policy.

Was the Black Diamond Therapeutics (BDTX) Form 4 transaction a stock purchase or a grant?

The Form 4 transaction was a grant/award acquisition, not an open-market purchase. Shares were issued as compensation under the non-employee director compensation policy after Prakash chose stock in lieu of cash for his annual director services.

How many BDTX shares does Raman Prakash hold after this Form 4 transaction?

After receiving 6,105 shares, Raman Prakash directly holds 37,132 shares of Black Diamond Therapeutics common stock. This updated total reflects only his direct ownership position as reported, following the compensation-related stock grant disclosed in the Form 4 filing.

What price was used to value the share grant to Black Diamond Therapeutics (BDTX) director Raman Prakash?

The grant to Raman Prakash was valued using a price of $2.15 per share. This price was based on the closing market price of Black Diamond Therapeutics common stock on March 19, 2026, as specified in the Form 4 footnotes.

Why did Black Diamond Therapeutics (BDTX) issue shares instead of cash to director Raman Prakash?

Shares were issued according to the company’s Fifth Amended and Restated Non-Employee Director Compensation Policy. Under this policy, Prakash elected to receive common stock, rather than cash, as compensation for his annual service as a non-employee director of Black Diamond Therapeutics.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Raman Prakash

(Last) (First) (Middle)

C/O BLACK DIAMOND THERAPEUTICS, INC.

245 FIRST STREET, 18TH FLOOR

(Street)

CAMBRIDGE MASSACHUSETTS 02142

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Black Diamond Therapeutics, Inc. [ BDTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/20/2026		A(1)		6,105	A	$2.15(2)	37,132	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares were issued in accordance with the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer.

2. The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on March 19, 2026.

	/s/ Brent Hatzis-Schoch, Attorney-in-Fact	03/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)